Mineralys Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
MLYS Nasdaq 2830 mineralystx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Mineralys Therapeutics, Inc.

Mineralys Therapeutics (MLYS) Heads Into Earnings As Lorundrostat Hopes Meet Undervalued View - Aug 5th, 2026 5:10 am
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026 - Aug 4th, 2026 6:00 am
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Jul 27th, 2026 2:01 pm
A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date - Jul 16th, 2026 3:05 pm
What to Know About This Mineralys Insider Sale Before a December FDA Date - Jul 16th, 2026 2:57 pm
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger - Jul 3rd, 2026 7:41 am
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential? - Jul 2nd, 2026 1:58 pm
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision - Jun 23rd, 2026 3:39 pm
Mineralys Therapeutics (MLYS) Prices $150M Public Offering of Common Stock - Jun 17th, 2026 12:29 pm
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) - Jun 14th, 2026 8:00 am
Mineralys Therapeutics (MLYS) to Repurchase Potential Royalties for Lorundrostat - Jun 11th, 2026 4:20 am
Mineralys Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Jun 8th, 2026 2:05 pm
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - Jun 8th, 2026 5:00 am
Mineralys Deepens Lorundrostat Bet With Royalty Buyout And New Data - Jun 7th, 2026 4:08 pm
Mineralys Therapeutics (MLYS) Shares Encouraging Data for Lorundrostat Clinical Efficacy - Jun 5th, 2026 9:55 am
Mineralys Prices $150 Million Stock Offering, Repurchases Lorundrostat Royalty Obligations - Jun 3rd, 2026 5:35 am
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - Jun 3rd, 2026 4:05 am